STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

  1. Home
  2. News
  3. MRK

Merck & Co Stock Price, News & Analysis

MRK NYSE

Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.

Merck & Co. (NYSE: MRK) is a global pharmaceutical leader with a 350-year legacy of medical innovation. This news hub provides investors and healthcare professionals with direct access to official announcements, financial disclosures, and research developments shaping the company's trajectory.

Track MRK's latest regulatory milestones, clinical trial results, and strategic partnerships through verified press releases and curated analysis. Our repository includes earnings call transcripts, FDA approval updates, and global health initiatives—all organized for efficient research and due diligence.

Key updates on therapeutic advancements in oncology, vaccines, and infectious diseases are maintained alongside financial performance data. Bookmark this page for real-time access to Merck's corporate communications and market-moving developments in the pharmaceutical sector.

News

ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season

Rhea-AI Summary

Merck (NYSE: MRK) announced that the CDC's Advisory Committee on Immunization Practices (ACIP) has recommended ENFLONSIA™ for preventing RSV lower respiratory tract disease in infants under 8 months of age. ENFLONSIA, recently FDA-approved, is the first and only RSV preventive option using the same dose regardless of infant weight.

The preventive monoclonal antibody provides protection through 5 months, covering a typical RSV season. Notably, ENFLONSIA has been included in the Vaccines for Children Program, enhancing accessibility. Merck plans to begin taking orders in July 2025, with deliveries scheduled before the 2025-2026 RSV season.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
none
-
News

Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention

Rhea-AI Summary

Merck (NYSE:MRK) has announced a virtual investor event scheduled for July 17, 2025, at 9:00 a.m. ET. During this event, the company's scientific and commercial team leaders will present an overview of Merck's advancing research pipeline focused on HIV treatment and prevention.

The presentation will be accessible via webcast to investors, analysts, media representatives, and the general public. Institutional investors and analysts will have the opportunity to participate in a Q&A session by dialing in using the provided information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
none
-
News

Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)

Rhea-AI Summary
Merck announced positive Phase 3 HYPERION trial results for WINREVAIR (sotatercept-csrk) in recently diagnosed adults with pulmonary arterial hypertension (PAH). The study met its primary endpoint, demonstrating a significant reduction in clinical worsening events compared to placebo. The trial included patients with WHO Group 1 PAH, with 72.2% on double therapy within 12 months of initial diagnosis. HYPERION marks the third successful Phase 3 study for WINREVAIR, following STELLAR and ZENITH trials. The study was stopped early due to positive interim results, and patients were offered continued treatment through the SOTERIA open-label extension study. WINREVAIR, a first-in-class activin signaling inhibitor, is currently approved in over 45 countries based on STELLAR study results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
clinical trial
News

IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer

Rhea-AI Summary
Merck (MRK) and Daiichi Sankyo have initiated the IDeate-Prostate01 phase 3 trial for ifinatamab deruxtecan (I-DXd), a potential first-in-class B7-H3 directed antibody drug conjugate, in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial will evaluate I-DXd against docetaxel in patients whose disease progressed during or after androgen receptor pathway inhibitor treatment. This marks the third pivotal trial in the I-DXd development program. The decision follows promising results from the IDeate-PanTumor01 phase 1/2 trial presented at ESMO 2022 and 2023. The development addresses a significant medical need, as advanced prostate cancer's five-year survival rate drops to 31%, compared to 90% for localized cases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
clinical trial
-
News

FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent

Rhea-AI Summary
Merck announced FDA approval of KEYTRUDA (pembrolizumab) for treating resectable locally advanced head and neck squamous cell carcinoma (HNSCC) with PD-L1 expression. This marks the first perioperative anti-PD-1 treatment regimen for this condition. Based on the Phase 3 KEYNOTE-689 trial, KEYTRUDA showed significant efficacy, reducing the risk of event-free survival events by 30% compared to standard care. The median EFS was 59.7 months for KEYTRUDA versus 29.6 months for standard care. The approval introduces a new treatment paradigm where KEYTRUDA is used before surgery (neoadjuvant), after surgery with radiotherapy/cisplatin (adjuvant), and then as a single agent. The drug demonstrated a manageable safety profile, though immune-mediated adverse reactions can occur. This approval was reviewed under Project Orbis, with applications under review globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
fda approval
-
News

Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs

Rhea-AI Summary
Merck Animal Health (NYSE:MRK) has received a positive opinion from the European Medicines Agency's CVMP for NUMELVI (atinvicitinib) Tablets for Dogs. NUMELVI is set to become the first and only second-generation JAK inhibitor for treating pruritus associated with allergic dermatitis and atopic dermatitis in dogs. The once-daily treatment is at least 10-fold more selective for JAK1 compared to other JAK family members, offering a superior safety profile while maintaining efficacy. Notable features include its use in dogs as young as six months old, effectiveness from the first dose, and no impact on vaccination immune response. The treatment addresses a significant market, as itch affects over 20% of dogs in general veterinary practice. European Commission's marketing authorization decision is expected in Q3 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
News

Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate

Rhea-AI Summary
Merck (NYSE: MRK) has initiated MOBILIZE-1, its first Phase 3 clinical trial for V181, a novel quadrivalent dengue vaccine candidate. The study aims to evaluate the safety, immunogenicity, and efficacy of a single-dose vaccine designed to prevent dengue disease caused by all four dengue virus serotypes, regardless of prior exposure. The trial has begun recruitment in Singapore, marking a significant milestone in addressing this widespread mosquito-borne disease that threatens approximately half of the world's population. V181 could potentially offer a crucial single-dose preventive option for at-risk populations globally. Merck plans to conduct trials in various regions where dengue poses a significant health threat.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
clinical trial
-
News

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season

Rhea-AI Summary
The FDA has approved Merck's (MRK) ENFLONSIA (clesrovimab-cfor), a preventive monoclonal antibody for RSV lower respiratory tract disease in infants. As the first RSV preventive with a uniform 105 mg dose regardless of weight, ENFLONSIA provides protection through 5 months. In the Phase 2b/3 CLEVER trial, ENFLONSIA demonstrated a 60.5% reduction in RSV-associated medically attended lower respiratory infections and an 84.3% reduction in RSV-associated hospitalizations compared to placebo. The drug is expected to be available before the 2025-2026 RSV season, with ordering beginning in July 2025. The CDC's Advisory Committee on Immunization Practices will meet to discuss recommendations for ENFLONSIA's use in infants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
fda approval
-
News

Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia

Rhea-AI Summary
Merck (MRK) announced positive topline results from two Phase 3 trials (CORALreef HeFH and CORALreef AddOn) evaluating enlicitide decanoate, a potential first-in-class oral PCSK9 inhibitor for hyperlipidemia treatment. Both trials met primary and key secondary endpoints, showing significant LDL-C reductions compared to placebo and other oral non-statin therapies. The CORALreef HeFH trial demonstrated efficacy in patients with heterozygous familial hypercholesterolemia, while CORALreef AddOn showed superior results versus ezetimibe and bempedoic acid. The drug showed a favorable safety profile with no meaningful differences in adverse events. The CORALreef program aims to enroll approximately 17,000 patients across several trials, including ongoing CORALreef Lipids and CORALreef Outcomes studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
clinical trial
News

Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Rhea-AI Summary
Merck (NYSE: MRK) announced that its chairman and CEO Robert M. Davis, along with Dr. Dean Y. Li, executive vice president and president of Merck Research Laboratories, will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference. The event is scheduled for Tuesday, June 10, 2025, at 10:00 a.m. EDT. The presentation will be accessible via live audio webcast to investors, analysts, media representatives, and the general public.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
conferences

FAQ

What is the current stock price of Merck & Co (MRK)?

The current stock price of Merck & Co (MRK) is $96.43 as of November 18, 2025.

What is the market cap of Merck & Co (MRK)?

The market cap of Merck & Co (MRK) is approximately 230.5B.
Stock MRK logo
Merck & Co

NYSE:MRK

MRK Rankings

#51 Ranked by Market Cap
#1072 Ranked by Dividends

MRK Stock Data

230.48B
2.48B
0.07%
80.59%
0.95%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
RAHWAY